Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the national Wilms' tumor study group

D. M. Green, N. E. Breslow, J. B. Beckwith, M. L. Ritchey, R. C. Shamberger, G. M. Haase, G. J. D'Angio, E. Perlman, M. Donaldson, P. E. Grundy, R. Weetman, M. J. Coppes, M. Malogolowkin, P. Shearer, P. Coccia, M. Kletzel, P. R.M. Thomas, R. Macklis, G. Tomlinson, V. HuffR. Newbury, D. Weeks

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Purpose: Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. Patients and Methods: A study of nephrectomy only for the tratment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90% or lower. Results: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5%. The 2-year survival rate is 100% with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2%, and the 2-year cumulative risk of metachronous contralateral WT was 3.1%. Conclusion: Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5% 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.

Original languageEnglish (US)
Pages (from-to)3719-3724
Number of pages6
JournalJournal of Clinical Oncology
Volume19
Issue number17
DOIs
StatePublished - Sep 1 2001

Fingerprint

Wilms Tumor
Nephrectomy
Histology
Recurrence
Survival Rate
Therapeutics
Disease-Free Survival
Clinical Trials
Lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Green, D. M., Breslow, N. E., Beckwith, J. B., Ritchey, M. L., Shamberger, R. C., Haase, G. M., ... Weeks, D. (2001). Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the national Wilms' tumor study group. Journal of Clinical Oncology, 19(17), 3719-3724. https://doi.org/10.1200/JCO.2001.19.17.3719

Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor : A report from the national Wilms' tumor study group. / Green, D. M.; Breslow, N. E.; Beckwith, J. B.; Ritchey, M. L.; Shamberger, R. C.; Haase, G. M.; D'Angio, G. J.; Perlman, E.; Donaldson, M.; Grundy, P. E.; Weetman, R.; Coppes, M. J.; Malogolowkin, M.; Shearer, P.; Coccia, P.; Kletzel, M.; Thomas, P. R.M.; Macklis, R.; Tomlinson, G.; Huff, V.; Newbury, R.; Weeks, D.

In: Journal of Clinical Oncology, Vol. 19, No. 17, 01.09.2001, p. 3719-3724.

Research output: Contribution to journalArticle

Green, DM, Breslow, NE, Beckwith, JB, Ritchey, ML, Shamberger, RC, Haase, GM, D'Angio, GJ, Perlman, E, Donaldson, M, Grundy, PE, Weetman, R, Coppes, MJ, Malogolowkin, M, Shearer, P, Coccia, P, Kletzel, M, Thomas, PRM, Macklis, R, Tomlinson, G, Huff, V, Newbury, R & Weeks, D 2001, 'Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the national Wilms' tumor study group', Journal of Clinical Oncology, vol. 19, no. 17, pp. 3719-3724. https://doi.org/10.1200/JCO.2001.19.17.3719
Green, D. M. ; Breslow, N. E. ; Beckwith, J. B. ; Ritchey, M. L. ; Shamberger, R. C. ; Haase, G. M. ; D'Angio, G. J. ; Perlman, E. ; Donaldson, M. ; Grundy, P. E. ; Weetman, R. ; Coppes, M. J. ; Malogolowkin, M. ; Shearer, P. ; Coccia, P. ; Kletzel, M. ; Thomas, P. R.M. ; Macklis, R. ; Tomlinson, G. ; Huff, V. ; Newbury, R. ; Weeks, D. / Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor : A report from the national Wilms' tumor study group. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 17. pp. 3719-3724.
@article{3787415e5fee4ab08f2a7202ebc93a86,
title = "Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the national Wilms' tumor study group",
abstract = "Purpose: Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. Patients and Methods: A study of nephrectomy only for the tratment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90{\%} or lower. Results: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5{\%}. The 2-year survival rate is 100{\%} with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2{\%}, and the 2-year cumulative risk of metachronous contralateral WT was 3.1{\%}. Conclusion: Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5{\%} 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.",
author = "Green, {D. M.} and Breslow, {N. E.} and Beckwith, {J. B.} and Ritchey, {M. L.} and Shamberger, {R. C.} and Haase, {G. M.} and D'Angio, {G. J.} and E. Perlman and M. Donaldson and Grundy, {P. E.} and R. Weetman and Coppes, {M. J.} and M. Malogolowkin and P. Shearer and P. Coccia and M. Kletzel and Thomas, {P. R.M.} and R. Macklis and G. Tomlinson and V. Huff and R. Newbury and D. Weeks",
year = "2001",
month = "9",
day = "1",
doi = "10.1200/JCO.2001.19.17.3719",
language = "English (US)",
volume = "19",
pages = "3719--3724",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "17",

}

TY - JOUR

T1 - Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor

T2 - A report from the national Wilms' tumor study group

AU - Green, D. M.

AU - Breslow, N. E.

AU - Beckwith, J. B.

AU - Ritchey, M. L.

AU - Shamberger, R. C.

AU - Haase, G. M.

AU - D'Angio, G. J.

AU - Perlman, E.

AU - Donaldson, M.

AU - Grundy, P. E.

AU - Weetman, R.

AU - Coppes, M. J.

AU - Malogolowkin, M.

AU - Shearer, P.

AU - Coccia, P.

AU - Kletzel, M.

AU - Thomas, P. R.M.

AU - Macklis, R.

AU - Tomlinson, G.

AU - Huff, V.

AU - Newbury, R.

AU - Weeks, D.

PY - 2001/9/1

Y1 - 2001/9/1

N2 - Purpose: Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. Patients and Methods: A study of nephrectomy only for the tratment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90% or lower. Results: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5%. The 2-year survival rate is 100% with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2%, and the 2-year cumulative risk of metachronous contralateral WT was 3.1%. Conclusion: Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5% 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.

AB - Purpose: Children younger than 24 months with small (< 550 g), favorable histology (FH) Wilms tumors (WTs) were shown in a pilot study to have an excellent prognosis when treated with nephrectomy only. Patients and Methods: A study of nephrectomy only for the tratment of selected children with FH WT was undertaken. Stringent stopping rules were designed to insure closure of the study if the true 2-year relapse-free survival rate was 90% or lower. Results: Seventy-five previously untreated children younger than 24 months with stage I/FH WTs for which the surgical specimen weighed less than 550 g were treated with nephrectomy only. Three patients developed metachronous, contralateral WT 1.1, 1.4, and 2.3 years after nephrectomy, and eight patients relapsed 0.3 to 1.05 years after diagnosis (median, 0.4 years; mean, 0.51 years). The sites of relapse were lung (n = 5) and operative bed (n = 3). The 2-year disease-free (relapse and metachronous contralateral WT) survival rate was 86.5%. The 2-year survival rate is 100% with a median follow-up of 2.84 years. The 2-year disease-free survival rate (excluding metachronous contralateral WT) was 89.2%, and the 2-year cumulative risk of metachronous contralateral WT was 3.1%. Conclusion: Children younger than 24 months treated with nephrectomy only for a stage I/FH WT that weighed less than 550 g had a risk of relapse, including the development of metachronous contralateral WT, of 13.5% 2 years after diagnosis. All patients who experienced relapse on this trial are alive at this time. This approach will be re-evaluated in a clinical trial using a less conservative stopping rule.

UR - http://www.scopus.com/inward/record.url?scp=0035449082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035449082&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.17.3719

DO - 10.1200/JCO.2001.19.17.3719

M3 - Article

C2 - 11533093

AN - SCOPUS:0035449082

VL - 19

SP - 3719

EP - 3724

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 17

ER -